RxDoctor Payments DataLook up a doctor →

Cara Ann East

Interventional Cardiology · Dallas, TXNPI 1770530420

Payments from drug & device makers

$2,978,511in general payments, 2019–2025

Across 898 payments — averaging $3316.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.8M
  • Amgen$429K
  • Eli Lilly$337K
  • Esperion Therapeutics, Inc.$160K
  • Boehringer Ingelheim International GmbH$144K
  • Novo Nordisk AS$53K
  • plus $102K from 16 others
$98,153in research payments, 2019–2025

Across 9 payments — averaging $10,906 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$71K
  • Novartis$27K
  • Novartis Pharma AG$184

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,978,511 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Other interventional cardiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →